Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurocrine Bioscienc
(NQ:
NBIX
)
143.03
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
143.03
Bid (Size)
134.91 (1)
Ask (Size)
152.26 (1)
Prev. Close
143.03
Today's Range
143.03 - 143.03
52wk Range
89.04 - 148.37
Shares Outstanding
100,600,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
May 01, 2024
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72.
Via
Investor's Business Daily
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
May 01, 2024
Via
Benzinga
Performance
YTD
+8.58%
+8.58%
1 Month
+1.17%
+1.17%
3 Month
+2.33%
+2.33%
6 Month
+28.23%
+28.23%
1 Year
+38.26%
+38.26%
More News
Read More
NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024
May 01, 2024
Via
InvestorPlace
No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win
May 01, 2024
Via
Investor's Business Daily
Sarepta Therapeutics Stock Shows Improved Technical Strength
April 29, 2024
Via
Investor's Business Daily
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
April 26, 2024
Via
Investor's Business Daily
3 Red-Hot Biotech Rockets Blasting Off in 2024
April 24, 2024
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
April 23, 2024
Via
Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
April 23, 2024
Via
Investor's Business Daily
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
April 16, 2024
From
Sentia Medical Sciences, Inc.
Via
GlobeNewswire
The 5 Stocks Most Sold By Insiders This Year
April 16, 2024
Via
MarketBeat
Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.
April 11, 2024
Via
Chartmill
Where Neurocrine Biosciences Stands With Analysts
April 10, 2024
Via
Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.
April 10, 2024
Via
Chartmill
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
April 05, 2024
Via
Chartmill
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
March 23, 2024
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
NASDAQ:NBIX is not too expensive for the growth it is showing.
March 20, 2024
Via
Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
March 20, 2024
Via
Chartmill
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
March 19, 2024
Via
Benzinga
Why Quality-Oriented Investors Should Consider NASDAQ:NBIX.
March 15, 2024
Via
Chartmill
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
March 13, 2024
Via
Benzinga
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
March 18, 2024
Via
Investor's Business Daily
AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base
March 16, 2024
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
NASDAQ:NBIX is probably undervalued for the fundamentals it is displaying.
March 14, 2024
Via
Chartmill
In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences
March 13, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.